Managing T2DM requires a multifaceted approach that includes not only lifestyle changes and glycemic control but also reducing the overall cardiovascular risk through guided interventions based on cardiovascular (CV) risk factors [2] and the use of glucose-lowering agents with proven CV benefits [3], such as SGLT2 inhibitors [4] and GLP-1 receptor agonists [5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.